A single center non randomized open-label comparative study using historical controls to verify the effectiveness of plasma exchange therapy for patients with anti-MDA 5 antibody positive rapidly progressive interstitial pneumonia

A single center non randomized open-label comparative study using historical controls to verify the effectiveness of plasma exchange therapy for patients with anti-MDA 5 antibody positive rapidly progressive interstitial pneumonia - Efficacy of plasma exchange therapy for anti-MDA5 antibody positive interstitial pneumonia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032000

Enrollment

Registered

2018-04-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial pneumonia

Interventions

Plasma exchange. Plasma exchange therapy should be performed once with 2.0 to 3.0 L and three times as one course. Nafamostat mesilate is used as an anticoagulant and fresh frozen plasma is used as a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who was newly developed or relapsed this time diagnosed as anti-MDA5 antibody positive interstitial pneumonia which is treatment-resistant to standard treatment acquired agreement over 20 years in writing.

Exclusion criteria

Exclusion criteria: When there is withdrawal of consent of research cooperation from research subjects. When the whole research is canceled. In cases where the researcher judges that the cancellation of research is appropriate for other reasons. When adverse reactions with difficult plasma continuation therapy appear.

Design outcomes

Primary

Measure	Time frame
One year survival rate	—

Countries

Japan

Contacts

Public ContactYoshiyuki Abe

Juntendo university Department of Internal Medicine and Rheumatology

yo-abe@juntendo.ac.jp0338133111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026